(Q35134646)

6 August 2017

1 reference

title

VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools (English)

1 reference

6 August 2017

David Pozo

1

1 reference

6 August 2017

publication date

1 May 2003

1 reference

Trends in Molecular Medicine

6 August 2017

published in

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

211-217

1 reference

Polypeptide with Broad Biological Activity: Isolation from Small Intestine

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal polypeptide (VIP) innervation of rat spleen, thymus, and lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Release of vasoactive intestinal polypeptide in mast cells by histamine liberators

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Demonstration of immunoreactive vasoactive intestinal peptide (IR-VIP) and somatostatin (IR-SOM) in rat thymus.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide regulation of granulomatous inflammation in murine Schistosomiasis mansoni

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Occurrence of vasoactive intestinal peptide (VIP) in lymphoid organs from rat and mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Gene expression of VIP receptor in rat lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Pituitary adenylate-cyclase-activating polypeptide expression in the immune system

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Regulation of VIP production and secretion by murine lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Cutting edge: is vasoactive intestinal peptide a type 2 cytokine?

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Differential activation of phospholipase D by VPAC and PAC1 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Differential signal transduction by five splice variants of the PACAP receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

In vitro properties of a high affinity selective antagonist of the VIP1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Interaction of vasoactive intestinal peptide with human blood mononuclear cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Enhancement by vasoactive intestinal peptide of gamma-interferon production by antigen-stimulated type 1 helper T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide receptor-1 (VPAC-1) is a novel gene target of the hemolymphopoietic transcription factor Ikaros

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Control of lymphocyte development by the Ikaros gene family

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Molecular cloning of a novel transcriptional repressor protein of the rat type 1 vasoactive intestinal peptide receptor gene

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Immunology of VIP: a review and therapeutical perspectives.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide inhibits IL-8 production in human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit LPS-stimulated MIP-1alpha production and mRNA expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Vasoactive intestinal peptide binding autoantibodies in autoimmune humans and mice

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

Immunobiology of vasoactive intestinal peptide (VIP)

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900049-2

7 January 2021

10.1016/S1471-4914(03)00049-2

Identifiers

DOI

1 reference

6 August 2017

1 reference